Physical activity study for people with severe asthma starting tezepelumab
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether a physical activity program can help people with severe asthma achieve better control and reduce flare-ups when added to a new treatment called tezepelumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have severe asthma diagnosed by a doctor.
- You are eligible to start tezepelumab (a biologic injection) based on UK guidelines.
- You have had at least 3 bad asthma attacks needing steroid pills in the last year, or you take daily steroid pills for asthma.
- Your asthma has been confirmed with breathing tests like reversibility or bronchial challenge.
- Your severe asthma team has already decided you should start tezepelumab before joining this study.
- You can and want to provide written permission to be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
This study tests if a personalized exercise program can help adults with severe asthma who are starting a new biologic treatment. It aims to improve symptoms and quality of life.
This trial tests if a drug called Tezepelumab can help adults with asthma who visit the emergency room. It aims to reduce severe asthma attacks and improve breathing control.
This trial looks at whether people with severe asthma who are taking the biologic tezepelumab can safely reduce their use of inhaled corticosteroids (ICS). It aims to see if reducing or stopping ICS affects asthma symptoms or flare-ups.
This trial tests if adding house dust mite allergy tablets (Acarizax) to tezepelumab (Tezspire) helps adults with severe allergic asthma stay in control. It is for people who are still struggling with asthma despite current treatments.
This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.
Hear when a new Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.